BL
IPXL

Balentine LLC’s Impax Laboratories, Inc. IPXL Stock Holding History

Balentine LLC’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-60
Closed -$1K – 619
2017
Q4 		$1K Hold
60
– – ﹤0.01% 625
2017
Q3 		$1K Hold
60
– – ﹤0.01% 641
2017
Q2 		$1K Hold
60
– – ﹤0.01% 605
2017
Q1 		$1K Buy
+60
New +$725 ﹤0.01% 573

Other funds holding IPXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TG
TCW Group Los Angeles, California $13.3B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balentine LLC's IPXL Position: Q1 2018 in Review

Balentine LLC sold out of Impax Laboratories, Inc. (IPXL) in Q1 2018, closing a stake of 60 shares — an estimated $1K sold.

Balentine LLC first reported a position in IPXL in Q1 2017 and held it in 4 quarters. The position peaked at $1K in Q4 2017. 188 funds tracked by Wall St. Rank hold IPXL as of Q1 2018.

  • Balentine LLC reported no remaining Impax Laboratories, Inc. position as of Q1 2018 after selling out during the quarter.
  • Balentine LLC sold 60 Impax Laboratories, Inc. shares in Q1 2018, an estimated $1K.
  • Balentine LLC first reported a position in Impax Laboratories, Inc. in Q1 2017 and held it in 4 quarters.
  • Balentine LLC's Impax Laboratories, Inc. position peaked at $1K in Q4 2017.
  • 188 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2018.

Based on Balentine LLC's 13F filing for Q1 2018, filed 16 May 2018.